← All trials
NCT04014257
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 25, 2019
- Primary completion
- Jul 31, 2020
- Completion date
- Dec 31, 2020
- First posted
- —
- Last posted
- —
- Enrollment
- 25
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- National OncoVentureLead sponsor
- The National Cancer CenterOverall official - principal investigator
- Seoul National UniversityOverall official - principal investigator
- Yonsei UniversityOverall official - principal investigator
- Handok Pharmaceuticals Co., Ltd.Collaborator
- CMG Pharmaceutical Co. LtdCollaborator
- Cha Medical UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.